Redeye comments on Camurus’ first quarter report 2025, which saw Buvidal sales on track, but Brixadi sales were flat Q/Q on a constant FX basis. We believe the slack in growth is temporary, but we reduce the projected near- and medium-term sales of Brixadi slightly.
LÄS MER
